Jan Skvarka
Director · Zentalis Pharmaceuticals, Inc.
Individual
- 2026
- Jun 18, 2026
- 2
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Jan Skvarka files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- WALTERS GROUP - $22.92M in ZNTL purchases and sales in the last 12 months
- Filip Janku - $1.38M in GLUE purchases and sales in the last 12 months
- Markus Warmuth - $951K in GLUE purchases and sales in the last 12 months
- Edmund Dunn - $483K in GLUE purchases and sales in the last 12 months
- Sharon Townson - $424K in GLUE purchases and sales in the last 12 months
- Anthony M. Manning - $411K in GLUE purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Jan Skvarka?
Jan Skvarka is a corporate insider, tracked as Director of Zentalis Pharmaceuticals, Inc. (ZNTL). InsiderAlpha holds 2 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
When did Jan Skvarka last file a Form 4?
The most recent primary Form 4 on record is dated 18 June 2026, one of 2 filings going back to 2026.
